Preclinical efficacy and dosimetry of CD44v6-directed terbium-161 radionuclide therapy
Amanda Gustafsson, Anja Charlotte Lundgren Mortensen, Veronica Rondahl, Tianqi Xu, Klas Bratteby, Peter Bernhardt, Marika Nestor · 2026
Read Preclinical efficacy and dosimetry of CD44v6-directed terbium-161 radionuclide therapy by Amanda Gustafsson, Anja Charlotte Lundgren Mortensen, Veronica Rondahl, Tianqi Xu, Klas Bratteby, Peter Bernhardt, Marika Nestor (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13549377.txt.
Description
Gustafsson and six co-authors test a new ray-based cancer drug in mice in this twenty twenty-six study. The drug homes to a mark found on some harsh tumor types and brings a rare ray source with it. A kin drug with a more common ray source is in human tests now.
Inside, the new drug bound tightly to marked cells in dish tests and piled up in graft tumors in mice. One tumor type soaked up a very high share of the dose in its tissue. Dose-linked tumor shrink showed in two graft types, with mild and short-lived blood effects. No harm showed in the kidneys, liver, or spleen of the treated mice.
Catalog record
| CREATOR | Amanda Gustafsson, Anja Charlotte Lundgren Mortensen, Veronica Rondahl, Tianqi Xu, Klas Bratteby, Peter Bernhardt, Marika Nestor |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 34 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |